Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endo...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 December 2018
|
| In: |
BMC ophthalmology
Year: 2018, Jahrgang: 18 |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/s12886-018-0978-9 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12886-018-0978-9 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12886-018-0978-9 
|
| Verfasserangaben: | Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 158583341X | ||
| 003 | DE-627 | ||
| 005 | 20220307121848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181221s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12886-018-0978-9 |2 doi | |
| 035 | |a (DE-627)158583341X | ||
| 035 | |a (DE-576)51583341X | ||
| 035 | |a (DE-599)BSZ51583341X | ||
| 035 | |a (OCoLC)1264023209 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Merz, Patrick |e VerfasserIn |0 (DE-588)1052826318 |0 (DE-627)789090384 |0 (DE-576)408561726 |4 aut | |
| 245 | 1 | 0 | |a Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |c Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack |
| 264 | 1 | |c 11 December 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.12.2018 | ||
| 520 | |a Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. | ||
| 700 | 1 | |a Ballikaya, Seda |e VerfasserIn |0 (DE-588)1033922064 |0 (DE-627)743671767 |0 (DE-576)381600513 |4 aut | |
| 700 | 1 | |a Auffarth, Gerd U. |d 1964- |e VerfasserIn |0 (DE-588)123385261 |0 (DE-627)577130420 |0 (DE-576)293687277 |4 aut | |
| 700 | 1 | |a Schmack, Ingo |d 1970- |e VerfasserIn |0 (DE-588)123840333 |0 (DE-627)70644633X |0 (DE-576)293903026 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC ophthalmology |d London : BioMed Central, 2001 |g 18(2018), Artikel-ID 316 |h Online-Ressource |w (DE-627)331018772 |w (DE-600)2050436-6 |w (DE-576)107014939 |x 1471-2415 |7 nnas |a Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g elocationid:316 |g extent:8 |a Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12886-018-0978-9 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12886-018-0978-9 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181221 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123840333 |a Schmack, Ingo |m 123840333:Schmack, Ingo |p 5 |y j | ||
| 998 | |g 123385261 |a Auffarth, Gerd U. |m 123385261:Auffarth, Gerd U. |d 910000 |d 910900 |e 910000PA123385261 |e 910900PA123385261 |k 0/910000/ |k 1/910000/910900/ |p 4 | ||
| 998 | |g 1033922064 |a Ballikaya, Seda |m 1033922064:Ballikaya, Seda |d 910000 |d 910900 |e 910000PB1033922064 |e 910900PB1033922064 |k 0/910000/ |k 1/910000/910900/ |p 3 | ||
| 998 | |g 1052826318 |a Merz, Patrick |m 1052826318:Merz, Patrick |d 50000 |e 50000PM1052826318 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN158583341X |e 3038936618 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 21.12.2018"],"language":["eng"],"relHost":[{"title":[{"title_sort":"BMC ophthalmology","title":"BMC ophthalmology"}],"disp":"Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cellsBMC ophthalmology","origin":[{"publisher":"BioMed Central","publisherPlace":"London","dateIssuedKey":"2001","dateIssuedDisp":"2001-"}],"part":{"volume":"18","extent":"8","text":"18(2018), Artikel-ID 316","year":"2018"},"id":{"eki":["331018772"],"issn":["1471-2415"],"zdb":["2050436-6"]},"language":["eng"],"pubHistory":["1.2001 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 28.07.2021"],"recId":"331018772","physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"8 S."}],"recId":"158583341X","type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack"]},"title":[{"title_sort":"Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells","title":"Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells"}],"origin":[{"dateIssuedDisp":"11 December 2018","dateIssuedKey":"2018"}],"id":{"doi":["10.1186/s12886-018-0978-9"],"eki":["158583341X"]},"person":[{"given":"Patrick","display":"Merz, Patrick","role":"aut","family":"Merz"},{"family":"Ballikaya","role":"aut","display":"Ballikaya, Seda","given":"Seda"},{"display":"Auffarth, Gerd U.","role":"aut","family":"Auffarth","given":"Gerd U."},{"display":"Schmack, Ingo","role":"aut","family":"Schmack","given":"Ingo"}]} | ||
| SRT | |a MERZPATRICEFFECTSOFR1120 | ||